Table 3.
Crude incidence rates per 100 000 person-years, number of cancer cases and SIRs of non-Hodgkin's lymphoma and Hodgkin’s lymphoma in patients with IBD in Sweden, 2005–2016*
| Parameters | Non-Hodgkin’s lymphoma | Hodgkin’s lymphoma | ||||
| IR (95% CI) | O/E | SIR (95% CI) | IR (95% CI) | O/E | SIR (95% CI) | |
| Total | 31.1 (23.2 to 41.8) | 44/36.7 | 1.2 (0.9 to 1.6) | 5.0 (2.0 to 10.4) | 7/3.7 | 1.9 (0.9 to 4.0) |
| Immunosuppression therapy† | ||||||
| No anti-TNF-α therapy or thiopurines | 10.5 (1.5 to 74.3) | 29/32.6 | 0.9 (0.6 to 1.3) | 10.5 (1.5 to 74.4) | 4/2.9 | 1.4 (0.5 to 3.6) |
| Monotherapy of anti-TNF-α | – | 0/0.1 | – | – | 0/0 | – |
| Monotherapy of thiopurines | 46.5 (23.2 to 93.0) | 8/2.8 | 2.8 (1.4 to 5.7) | 11.6 (2.9 to 46.5) | 2/0.5 | 4.2 (1.1 to 16.9) |
| Combined therapy | 67.3 (32.1 to 141.2) | 7/1.2 | 5.7 (2.7 to 11.9) | 9.6 (1.4 to 68.4) | 1/0.3 | 3.5 (0.5 to 24.8) |
*The Swedish Prescribed Drug Register was available since 2005, therefore we included patients with IBD diagnosed from 2005; all patients were at risk from 1 year after initiation of treatment.
†Definitions of biological drugs and thiopurines according to Anatomical Therapeutic Chemical codes in the Swedish Prescribed Drug Register are shown in online supplemental table 4.
E, expected number of cases; IBD, inflammatory bowel disease; IR, incidence rate, per 100 000 person-years; O, observed number of cases; SIR, standardised incidence ratio; TNF, tumour necrosis factor.